These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11807175)

  • 1. Designing inhibitors of cyclin-dependent kinases.
    Hardcastle IR; Golding BT; Griffin RJ
    Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
    Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
    J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitors.
    Fischer PM; Endicott J; Meijer L
    Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
    Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
    Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and synthesis of purine inhibitors of CDK2. III.
    Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
    Fischer PM; Lane DP
    Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
    J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
    Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecules as inhibitors of cyclin-dependent kinases.
    Huwe A; Mazitschek R; Giannis A
    Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
    Meijer L; Knockaert M; Damiens E
    Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
    Schulze-Gahmen U; De Bondt HL; Kim SH
    J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
    Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.